Lopinavir And Ritonavir Tablets

Warning and Precautions

The following have been observed in patients receivingLopinavir and Ritonavir: 

• Drug Interactions: Higher plasma concentrations of concomitant medications may occur; consider drug-drug interaction potential to reduce risk of serious or life-threatening adverse reactions.
• Pancreatitis: Fatalities have occurred; suspend therapy as clinically appropriate.
• Hepatotoxicity: Fatalities have occurred. Monitor liver function before and during therapy, especially in patients with underlying hepatic disease, including hepatitis B and hepatitis C, or marked transaminase elevations.
• QT interval prolongation and isolated cases of torsade de pointes have been reported although causality could not be established. Avoid use in patients with congenital long QT syndrome, those with hypokalemia, and with other drugs that prolong the QT interval.
• PR interval prolongation may occur in some patients. Cases of second and third degree heart block have been reported. Use with caution in patients with pre-existing conduction system disease, ischemic heart disease, cardiomyopathy, underlying structural heart disease or when administering with other drugs that may prolong the PR interval. 
• Patients may develop new onset or exacerbations of diabetes mellitus, hyperglycemia, immune reconstitution syndrome, redistribution/accumulation of body fat. 
• Total cholesterol and triglycerides elevations. Monitor prior to therapy and periodically thereafter.
• Hemophilia: Spontaneous bleeding may occur, and additional factor VIII may be required.